Can Liraglutide Delay Diabetes Onset?


Researchers compared time to onset of diabetes in a group of patients with obesity and pre-diabetes treated with liraglutide or placebo.

In a randomized, double-blind, placebo-controlled study comparing liraglutide 3 mg daily to placebo, the authors determined time to onset of diabetes as the main outcome measure. Results were published in the Lancet.

Patients in the study were classified as having pre-diabetes with elevated BMIs and were enrolled as an adjunct to dieting and increasing physical activity.

The time to onset of diabetes was 2.7 times longer in the liraglitide group.

Two percent of patients in the liraglutide group were diagnosed with diabetes vs 6% in the placebo group. Liraglutide also induced greater weight loss than placebo.

The authors concluded that liraglutide might reduce the risk the risk of diabetes in patients with obesity and pre-diabetes.

Related Videos
Should We Reclassify Diabetes Subtypes?
What Should the American Academy of Physician Associates Focus on in 2025?
GLP-1 Agonist Safety Risks and Obesity Stigma with Kevin Peterson, MD, MPH
Video 8 - "Pathophysiology of Hypercortisolism"
Video 7 - "Evolving Perception of Autonomous Adrenal Hypercortisolism "
A panel of 5 experts on Cushing's syndrome
A panel of 5 experts on Cushing's syndrome
Laxmi Mehta, MD | Credit: American Heart Association
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
© 2024 MJH Life Sciences

All rights reserved.